articleTop 1% cited

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Journal of Clinical Oncology · 2009 · Vol. 27(22) · pp. 3584–3590

Robert J. Motzer✉(Texas Oncology)Thomas E. Hutson(Texas Oncology)Piotr Tomczak(Texas Oncology)M. Dror Michaelson(Texas Oncology)Ronald M. Bukowski(Texas Oncology)Stéphane Oudard(Texas Oncology)Sylvie Négrier(Texas Oncology)Cezary Szczylik(Texas Oncology)Роберто Пили(Texas Oncology)Georg A. Bjarnason(Texas Oncology)Xavier García del Muro(Texas Oncology)Jeffrey A. Sosman(Texas Oncology)E Solska(Texas Oncology)George Wilding(Texas Oncology)John A. Thompson(Texas Oncology)Sindy T. Kim(Texas Oncology)Isan Chen(Texas Oncology)Xin Huang(Texas Oncology)Robert A. Figlin(Texas Oncology)

View via DOI Publisher page

Abstract

Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.

Renal cell carcinoma treatment Renal and related cancers Pancreatic and Hepatic Oncology ResearchMedicineSunitinibRenal cell carcinomaInternal medicineHazard ratioDiscontinuationAlpha interferonAdverse effectClinical endpointGastroenterology

MeSH terms

SunitinibAdministration, OralAdultAgedCarcinoma, Renal CellDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansIndolesInjections, SubcutaneousKidney NeoplasmsMaleMiddle Aged